אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - estradiol valerate, quantity: 2 mg - tablet, sugar coated - excipient ingredients: magnesium stearate; indigo carmine; macrogol 6000; sucrose; glycol montanate; titanium dioxide; calcium carbonate; povidone; maize starch; lactose monohydrate; glycerol; purified talc - indications as at 19 july 2004: short term treatment of climacteric complaints after the cessation of monthly bleeding, or deficiency symptoms after oophorectomy or radiological castration for non-carcinomatous diseases, such as hot flushes, outbreaks of sweat, sleep disturbances, depressive moods, irritability, headaches, dizziness. progynova has also a favourable influence on bladder irritation (a not infrequent occurrence in the climacteric), signs of cutaneous and mucosal involution (particularly in the genital region) which normally occur with advancing age.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - estradiol valerate, quantity: 1 mg - tablet, sugar coated - excipient ingredients: iron oxide yellow; glycerol; povidone; macrogol 6000; magnesium stearate; calcium carbonate; sucrose; titanium dioxide; glycol montanate; maize starch; purified talc; lactose monohydrate - indications as at 19 july 2004: short term treatment of climacteric complaints after the cessation of monthly bleeding, or deficiency symptoms after oophorectomy or radiological castration for non-carcinomatous diseases, such as hot flushes, outbreaks of sweat, sleep disturbances, depressive moods, irritability, headaches, dizziness. progynova has also a favourable influence on bladder irritation (a not infrequent occurrence in the climacteric), signs of cutaneous and mucosal involution (particularly in the genital region) which normally occur with advancing age.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

bayer new zealand limited - estradiol hemihydrate 7.84mg equivalent to estradiol 7.59 mg (100 µg/24h) - transdermal patch - 100 mcg/24h - active: estradiol hemihydrate 7.84mg equivalent to estradiol 7.59 mg (100 µg/24h) excipient: acrylates copolymer ethyl oleate glyceryl monolaurate isopropyl myristate - for short-term treatment of complaints associated with the menopause and post-menopause, including signs and symptoms of oestrogen deficiency, whether naturally or surgically induced. oestrogen replacement therapy in women with an intact uterus should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals. prevention of postmenopausal osteoporosis.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

bayer new zealand limited - estradiol hemihydrate 2.04mg equivalent to estradiol 1.97 mg (25 µg/24h) - transdermal patch - 25 mcg/24h - active: estradiol hemihydrate 2.04mg equivalent to estradiol 1.97 mg (25 µg/24h) excipient: acrylates copolymer ethyl oleate glyceryl monolaurate isopropyl myristate - for short-term treatment of complaints associated with the menopause and post-menopause, including signs and symptoms of oestrogen deficiency, whether naturally or surgically induced. oestrogen replacement therapy in women with an intact uterus should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals. prevention of postmenopausal osteoporosis.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

bayer new zealand limited - estradiol hemihydrate 3.92mg equivalent to estradiol 3.79 mg (50 µg/24h) - transdermal patch - 50 mcg/24h - active: estradiol hemihydrate 3.92mg equivalent to estradiol 3.79 mg (50 µg/24h) excipient: acrylates copolymer ethyl oleate glyceryl monolaurate isopropyl myristate - for short-term treatment of complaints associated with the menopause and post-menopause, including signs and symptoms of oestrogen deficiency, whether naturally or surgically induced. oestrogen replacement therapy in women with an intact uterus should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals. prevention of postmenopausal osteoporosis.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

bayer new zealand limited - estradiol hemihydrate 5.88mg equivalent to estradiol 5.69 mg (75µg/24h) - transdermal patch - 75 mcg/24h - active: estradiol hemihydrate 5.88mg equivalent to estradiol 5.69 mg (75µg/24h) excipient: acrylates copolymer ethyl oleate glyceryl monolaurate isopropyl myristate - for short-term treatment of complaints associated with the menopause and post-menopause, including signs and symptoms of oestrogen deficiency, whether naturally or surgically induced. oestrogen replacement therapy in women with an intact uterus should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals. prevention of postmenopausal osteoporosis.

סינגפור - אנגלית - HSA (Health Sciences Authority)

pfizer private limited - conjugated estrogens (ce) desiccation with lactose @4.29% ce - tablet, sugar coated - 0.3 mg - conjugated estrogens (ce) desiccation with lactose @4.29% ce 0.3 mg

סינגפור - אנגלית - HSA (Health Sciences Authority)

pfizer private limited - conjugated estrogens desiccation with lactose 14.57mg @4.29% ce - tablet, sugar coated - 0.625 mg - conjugated estrogens desiccation with lactose 14.57mg @4.29% ce 0.625 mg

קנדה - אנגלית - Health Canada

novo nordisk canada inc - estradiol; norethindrone acetate - tablet - 0.5mg; 0.1mg - estradiol 0.5mg; norethindrone acetate 0.1mg - progestins

ארצות הברית - אנגלית - NLM (National Library of Medicine)

meda pharmaceuticals inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 0.52 mg in 0.87 g -     elestrin is contraindicated in women with any of the following conditions: risk summary elestrin is not indicated for use in pregnancy. there are no data with the use of elestrin in pregnant women; however, epidemiologic studies and meta-analyses have not found an increased risk of genital or nongenital birth defects (including cardiac anomalies or limb-reduction defects) following exposure to combined hormonal contraceptives (estrogen and progestins) before conception or during early pregnancy. animal studies to evaluate embryo/fetal toxicity were not conducted with elestrin. risk summary estrogens are present in human milk and can reduce milk production in breast-feeding women. this reduction can occur at any time but is less likely to occur once breast-feeding is well-established. the developmental and health benefits of breast-feeding should be considered along with the mother’s clinical need for elestrin and any potential adverse effects on the breast-fed child from elestrin or from the underlying maternal condition. elestrin is not indicated in pediatric patients. clinical studies have not been conducted in the pediatric population. there have not been sufficient numbers of geriatric women involved in clinical studies utilizing elestrin to determine whether those over 65 years of age differ from younger subjects in their response to elestrin. in the whi estrogen-alone substudy (daily ce [0.625 mg]-alone versus placebo), there was a higher relative risk of stroke in women greater than 65 years of age [see clinical studies (14.2)] . in the whi estrogen plus progestin substudy (daily ce [0.625 mg] plus mpa [2.5 mg] versus placebo), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age [see clinical studies (14.2)] . in the whims ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen-alone or estrogen plus progestin when compared to placebo [see warnings and precautions (5.3), and clinical studies (14.3)] . since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women8  [see warnings and precautions (5.3), and clinical studies (14.3)] . elestrin® (el-les-strin) (estradiol gel) figure 1 to apply the dose, hold the pump with the tip facing the application area of the arm. for each pump depression needed, press the pump firmly and fully with a continuous motion without hesitation. figure 2 gently spread the gel using only 2 fingers. spread and gently rub in the gel over the entire area of your upper arm and shoulder area, as illustrated. elestrin should not be used after the date printed on the container (expiration date). what are the ingredients in elestrin? active ingredient: estradiol. inactive ingredients: purified water, ethanol, propylene glycol, diethylene glycol monoethyl ether, carbomer homopolymer type c, triethanolamine, and edetate disodium. elestrin is a registered trademark of meda pharma s.a.r.l., a viatris company. distributed by: meda pharmaceuticals inc. canonsburg, pa 15317 u.s.a. © 2024 viatris inc. rev. 12/2023 in-0480-08 141343-1223